Comment on a PREreview of "The Many Faces of Parkinsonism: Dissecting Clinical and Molecular Overlap in Multiple System Atrophy and Parkinson's Disease"

This Zenodo record is a permanently preserved version of a comment on a PREreview. You can view the complete PREreview and comments at https://prereview.org/reviews/18554240. This manuscript provides a comprehensive and well-structured overview of the clinical, molecular, and therapeutic distinctions between Multiple System Atrophy (MSA) and Parkinson's Disease (PD), successfully integrating clinical observations with emerging molecular and genomic evidence. The authors demonstrate strong conceptual organization, particularly in explaining MSA subtypes, geographical distribution patterns, and divergent therapeutic strategies, while effectively incorporating novel research approaches such as induced pluripotent stem cell (iPSC) modeling and synuclein-targeting therapies. The discussion of autonomic dysfunction and pharmacological management is particularly clear and clinically relevant. However, several areas could be strengthened to enhance the manuscript's scientific depth and clarity. The abstract would benefit from clarifying whether the proposed tailored therapeutic strategies represent novel treatment paradigms or adaptations of existing approaches. The section on emerging clinical trials should include expanded discussion of recently studied agents such as Lu AF82422 to improve currency and clinical relevance. Additional mechanistic explanation of biomarkers, including serum neurofilament light chain and alpha-synuclein seeding assays, would improve the translational connection between molecular findings and clinical diagnosis. The genomic variability section would benefit from clearer figure referencing to guide reader interpretation. Furthermore, the therapeutic comparison section should begin with a concise statement outlining its comparative purpose. The summary would be strengthened by including supporting quantitative or literature-based evidence regarding biomarker elevation and levodopa responsiveness. Finally, the manuscript would benefit from the inclusion of keywords and a dedicated future research section outlining emerging diagnostic tools and therapeutic targets. Addressing these revisions would substantially improve the manuscript's clarity, completeness, and impact within neurodegenerative disease research. Competing interests The author of this comment declares that they have no competing interests.